MedTrace Logo

A Phase 2 Trial of JKN24011 in COPD

NCT07440524 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 215

Last updated 2026-02-27

No results posted yet for this study

Summary

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Subcutaneous JKN24011 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)

Interventions

BIOLOGICAL

JKN24011

JKN24011 subcutaneous injection,Q4W

OTHER

Placebo

Placebo subcutaneous injection,Q4W

Sponsors & Collaborators

  • Joincare Pharmaceutical Group Industry Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2026-04-30
Completion
2026-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07440524 on ClinicalTrials.gov